Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,707 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Risks Clear all
Completed Not applicable Interventional

Focused Palliative Care Intervention in Advanced Heart Failure

NCT02805712
View directory record Official record
Conditions
Heart Failure, Quality of Life
Interventions
Verbal Information and Discussion, Control
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 24, 2026, 1:17 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cardioprotective Effects of Freeze Dried Grape Powder on Blood Pressure and Plasma Lipids/Lipoproteins

NCT03659695
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 24, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

A Dietary Study for People With Multiple Myeloma

NCT07226609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
nutrition counseling and coaching, dietary guidelines, research dietitian visit, Questionnaires, Frozen pre-prepared meals
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 24, 2026, 1:17 AM EDT
Recruiting Phase 2 Interventional

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Not applicable Interventional

A Novel Approach to Reducing Adiposity Among Young Men

NCT04267263
View directory record Official record
Conditions
Weight Loss, Men, Lifestyle Risk Reduction, Cardiovascular Diseases, Obesity
Interventions
Self-guided lifestyle intervention
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Jul 24, 2026, 1:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk

NCT01705951
View directory record Official record
Conditions
Smoking, Cardiovascular Disease Risk
Interventions
Resistance Training (RT), Nicotine Replacement Therapy (NRT)
Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Not applicable Interventional Results available

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

NCT03647475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Combination Product
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 24, 2026, 1:17 AM EDT
Completed No phase listed Observational

nuMoM2b Heart Health Study

NCT02231398
View directory record Official record
Conditions
Pregnancy Complicated by Cardiovascular Disorders as Postpartum Condition, Delivered During Previous Episode, Breathing-Related Sleep Disorder
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
15
States / cities
Fountain Valley, California • Long Beach, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support

NCT03812614
View directory record Official record
Conditions
Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
Interventions
FAM ACT, I-DSMES
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 75 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 24, 2026, 1:17 AM EDT
Terminated Not applicable Interventional Results available

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

NCT00106938
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions
Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical)
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence

NCT02955238
View directory record Official record
Conditions
Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
40 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Not applicable Interventional

Home Air Filtration for Traffic-Related Air Pollution

NCT04279249
View directory record Official record
Conditions
Cardiovascular Risk Factor, Blood Pressure
Interventions
HEPA Air Filtration, Sham HEPA Air Filtration
Other
Lead sponsor
UConn Health
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jul 24, 2026, 1:17 AM EDT
Not listed No phase listed Observational

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

NCT04115436
View directory record Official record
Conditions
Thromboembolic Events
Interventions
Not listed
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
Not listed
Enrollment
40 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Jul 24, 2026, 1:17 AM EDT
Not listed Not applicable Interventional

Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease

NCT03221114
View directory record Official record
Conditions
Uncontrolled Hypertension, Cardiovascular Risk Factor
Interventions
Positive Psychological Intervention
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Not applicable Interventional

A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions

NCT04382521
View directory record Official record
Conditions
Hyperlipemia, Hypertension, Type2 Diabetes
Interventions
Text Message Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 24, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study

NCT07185204
View directory record Official record
Conditions
Postpartum Preeclampsia
Interventions
Early detection and management of postpartum preeclampsia bundle
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 1:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

NCT00684957
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Recombinant Human Growth Hormone, Recombinant Human IGF-1
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 65 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Jul 24, 2026, 1:17 AM EDT
Terminated No phase listed Observational Results available

Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation

NCT00615719
View directory record Official record
Conditions
Acute Coronary Syndromes, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Jul 24, 2026, 1:17 AM EDT
Terminated No phase listed Observational

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 24, 2026, 1:17 AM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 24, 2026, 1:17 AM EDT
Recruiting Phase 2 Interventional

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

NCT07223385
View directory record Official record
Conditions
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
Interventions
Cardio-Oncology Referral, Notification to PCP/General Cardiologist
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 1:17 AM EDT
Not yet recruiting No phase listed Observational

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

NCT07588984
View directory record Official record
Conditions
Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
Interventions
Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
Behavioral · Drug
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 24, 2026, 1:17 AM EDT